

Global GLP-1/GIPR Dual Peptide Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G10F1243AA91EN.html>

Date: February 2026

Pages: 104

Price: US\$ 3,480.00 (Single User License)

ID: G10F1243AA91EN

Abstracts

According to our (Global Info Research) latest study, the global GLP-1/GIPR Dual Peptide Agonist market size was valued at US\$ 31093 million in 2025 and is forecast to a readjusted size of US\$ 65293 million by 2032 with a CAGR of 11.0% during review period.

In 2025, global GLP-1/GIPR Dual Peptide Agonist production reached approximately 156.36 M Units, with an average global market price of around 193.26 USD per Unit.

A GLP-1/GIPR Dual Peptide Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity. To date, Tirzepatide is the only commercially available GLP-1/GIPR Dual Peptide Agonist product in the world.

GLP-1/GIPR Dual Peptide Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs

and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma's most strategically important therapeutic area.

The upstream raw materials for GLP-1/GIPR Dual Peptide Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of GLP-1/GIPR Dual Peptide Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

This report is a detailed and comprehensive analysis for global GLP-1/GIPR Dual Peptide Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global GLP-1/GIPR Dual Peptide Agonist market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global GLP-1/GIPR Dual Peptide Agonist market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global GLP-1/GIPR Dual Peptide Agonist market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global GLP-1/GIPR Dual Peptide Agonist market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for GLP-1/GIPR Dual Peptide Agonist

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global GLP-1/GIPR Dual Peptide Agonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Asclepis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

GLP-1/GIPR Dual Peptide Agonist market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Injection

Oral Administration

Market segment by Receptor Agonist Properties

Balanced

Biased

Market segment by Medicinal Efficacy

Long-acting

Short-acting

Market segment by Application

Diabetes

Obesity

Others

Major players covered

Eli Lilly

Roche

Viking Therapeutics

Asclepis Pharma

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe GLP-1/GIPR Dual Peptide Agonist product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of GLP-1/GIPR Dual Peptide Agonist, with price, sales quantity, revenue, and global market share of GLP-1/GIPR Dual Peptide Agonist from 2021 to 2026.

Chapter 3, the GLP-1/GIPR Dual Peptide Agonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the GLP-1/GIPR Dual Peptide Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and GLP-1/GIPR Dual Peptide Agonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces

analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1/GIPR Dual Peptide Agonist.

Chapter 14 and 15, to describe GLP-1/GIPR Dual Peptide Agonist sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Aluminum-doped Cobalt Tetroxide Consumption Value by Type: 2021 Versus 2025 Versus 2032
 - 1.3.2 Large Particles (>10 ?m)
 - 1.3.3 Small Particles (?10 ?m)
- 1.4 Market Analysis by Doping Level
 - 1.4.1 Overview: Global Aluminum-doped Cobalt Tetroxide Consumption Value by Doping Level: 2021 Versus 2025 Versus 2032
 - 1.4.2 Doping Level 7000 ppm
- 1.5 Market Analysis by Application
 - 1.5.1 Overview: Global Aluminum-doped Cobalt Tetroxide Consumption Value by Application: 2021 Versus 2025 Versus 2032
 - 1.5.2 Automotive
 - 1.5.3 3C Electronics
 - 1.5.4 Power Tools
 - 1.5.5 Others
- 1.6 Global Aluminum-doped Cobalt Tetroxide Market Size & Forecast
 - 1.6.1 Global Aluminum-doped Cobalt Tetroxide Consumption Value (2021 & 2025 & 2032)
 - 1.6.2 Global Aluminum-doped Cobalt Tetroxide Sales Quantity (2021-2032)
 - 1.6.3 Global Aluminum-doped Cobalt Tetroxide Average Price (2021-2032)

2 MANUFACTURERS PROFILES

- 2.1 Jervois Global
 - 2.1.1 Jervois Global Details
 - 2.1.2 Jervois Global Major Business
 - 2.1.3 Jervois Global Aluminum-doped Cobalt Tetroxide Product and Services
 - 2.1.4 Jervois Global Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.1.5 Jervois Global Recent Developments/Updates
- 2.2 Zhejiang Huayou Cobalt
 - 2.2.1 Zhejiang Huayou Cobalt Details

- 2.2.2 Zhejiang Huayou Cobalt Major Business
- 2.2.3 Zhejiang Huayou Cobalt Aluminum-doped Cobalt Tetroxide Product and Services
- 2.2.4 Zhejiang Huayou Cobalt Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Zhejiang Huayou Cobalt Recent Developments/Updates
- 2.3 GEM Co.,Ltd.
- 2.3.1 GEM Co.,Ltd. Details
- 2.3.2 GEM Co.,Ltd. Major Business
- 2.3.3 GEM Co.,Ltd. Aluminum-doped Cobalt Tetroxide Product and Services
- 2.3.4 GEM Co.,Ltd. Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 GEM Co.,Ltd. Recent Developments/Updates
- 2.4 Jinchuan Group
- 2.4.1 Jinchuan Group Details
- 2.4.2 Jinchuan Group Major Business
- 2.4.3 Jinchuan Group Aluminum-doped Cobalt Tetroxide Product and Services
- 2.4.4 Jinchuan Group Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Jinchuan Group Recent Developments/Updates
- 2.5 CNGR Advanced Material
- 2.5.1 CNGR Advanced Material Details
- 2.5.2 CNGR Advanced Material Major Business
- 2.5.3 CNGR Advanced Material Aluminum-doped Cobalt Tetroxide Product and Services
- 2.5.4 CNGR Advanced Material Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 CNGR Advanced Material Recent Developments/Updates
- 2.6 Hezong Technology
- 2.6.1 Hezong Technology Details
- 2.6.2 Hezong Technology Major Business
- 2.6.3 Hezong Technology Aluminum-doped Cobalt Tetroxide Product and Services
- 2.6.4 Hezong Technology Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Hezong Technology Recent Developments/Updates
- 2.7 Ganfeng Lithium
- 2.7.1 Ganfeng Lithium Details
- 2.7.2 Ganfeng Lithium Major Business
- 2.7.3 Ganfeng Lithium Aluminum-doped Cobalt Tetroxide Product and Services

2.7.4 Ganfeng Lithium Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.7.5 Ganfeng Lithium Recent Developments/Updates

2.8 Shanghai Jayson New Energy Materials

2.8.1 Shanghai Jayson New Energy Materials Details

2.8.2 Shanghai Jayson New Energy Materials Major Business

2.8.3 Shanghai Jayson New Energy Materials Aluminum-doped Cobalt Tetroxide Product and Services

2.8.4 Shanghai Jayson New Energy Materials Aluminum-doped Cobalt Tetroxide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.8.5 Shanghai Jayson New Energy Materials Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: ALUMINUM-DOPED COBALT TETROXIDE BY MANUFACTURER

3.1 Global Aluminum-doped Cobalt Tetroxide Sales Quantity by Manufacturer (2021-2026)

3.2 Global Aluminum-doped Cobalt Tetroxide Revenue by Manufacturer (2021-2026)

3.3 Global Aluminum-doped Cobalt Tetroxide Average Price by Manufacturer (2021-2026)

3.4 Market Share Analysis (2025)

3.4.1 Producer Shipments of Aluminum-doped Cobalt Tetroxide by Manufacturer Revenue (\$MM) and Market Share (%): 2025

3.4.2 Top 3 Aluminum-doped Cobalt Tetroxide Manufacturer Market Share in 2025

3.4.3 Top 6 Aluminum-doped Cobalt Tetroxide Manufacturer Market Share in 2025

3.5 Aluminum-doped Cobalt Tetroxide Market: Overall Company Footprint Analysis

3.5.1 Aluminum-doped Cobalt Tetroxide Market: Region Footprint

3.5.2 Aluminum-doped Cobalt Tetroxide Market: Company Product Type Footprint

3.5.3 Aluminum-doped Cobalt Tetroxide Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Aluminum-doped Cobalt Tetroxide Market Size by Region

4.1.1 Global Aluminum-doped Cobalt Tetroxide Sales Quantity by Region (2021-2032)

4.1.2 Global Aluminum-doped Cobalt Tetroxide Consumption Value by Region (2021-2032)

- 4.1.3 Global Aluminum-doped Cobalt Tetroxide Average Price by Region (2021-2032)
- 4.2 North America Aluminum-doped Cobalt Tetroxide Consumption Value (2021-2032)
- 4.3 Europe Aluminum-doped Cobalt Tetroxide Consumption Value (2021-2032)
- 4.4 Asia-Pacific Aluminum-doped Cobalt Tetroxide Consumption Value (2021-2032)
- 4.5 South America Aluminum-doped Cobalt Tetroxide Consumption Value (2021-2032)
- 4.6 Middle East & Africa Aluminum-doped Cobalt Tetroxide Consumption Value (2021-2032)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Aluminum-doped Cobalt Tetroxide Sales Quantity by Type (2021-2032)
- 5.2 Global Aluminum-doped Cobalt Tetroxide Consumption Value by Type (2021-2032)
- 5.3 Global Aluminum-doped Cobalt Tetroxide Average Price by Type (2021-2032)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Aluminum-doped Cobalt Tetroxide Sales Quantity by Application (2021-2032)
- 6.2 Global Aluminum-doped Cobalt Tetroxide Consumption Value by Application (2021-2032)
- 6.3 Global Aluminum-doped Cobalt Tetroxide Average Price by Application (2021-2032)

7 NORTH AMERICA

- 7.1 North America Aluminum-doped Cobalt Tetroxide Sales Quantity by Type (2021-2032)
- 7.2 North America Aluminum-doped Cobalt Tetroxide Sales Quantity by Application (2021-2032)
- 7.3 North America Aluminum-doped Cobalt Tetroxide Market Size by Country
 - 7.3.1 North America Aluminum-doped Cobalt Tetroxide Sales Quantity by Country (2021-2032)
 - 7.3.2 North America Aluminum-doped Cobalt Tetroxide Consumption Value by Country (2021-2032)
 - 7.3.3 United States Market Size and Forecast (2021-2032)
 - 7.3.4 Canada Market Size and Forecast (2021-2032)
 - 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

8.1 Europe Aluminum-doped Cobalt Tetroxide Sales Quantity by Type (2021-2032)

8.2 Europe Aluminum-doped Cobalt Tetroxide Sales Quantity by Application (2021-2032)

8.3 Europe Aluminum-doped Cobalt Tetroxide Market Size by Country

8.3.1 Europe Aluminum-doped Cobalt Tetroxide Sales Quantity by Country (2021-2032)

8.3.2 Europe Aluminum-doped Cobalt Tetroxide Consumption Value by Country (2021-2032)

8.3.3 Germany Market Size and Forecast (2021-2032)

8.3.4 France Market Size and Forecast (2021-2032)

8.3.5 United Kingdom Market Size and Forecast (2021-2032)

8.3.6 Russia Market Size and Forecast (2021-2032)

8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

9.1 Asia-Pacific Aluminum-doped Cobalt Tetroxide Sales Quantity by Type (2021-2032)

9.2 Asia-Pacific Aluminum-doped Cobalt Tetroxide Sales Quantity by Application (2021-2032)

9.3 Asia-Pacific Aluminum-doped Cobalt Tetroxide Market Size by Region

9.3.1 Asia-Pacific Aluminum-doped Cobalt Tetroxide Sales Quantity by Region (2021-2032)

9.3.2 Asia-Pacific Aluminum-doped Cobalt Tetroxide Consumption Value by Region (2021-2032)

9.3.3 China Market Size and Forecast (2021-2032)

9.3.4 Japan Market Size and Forecast (2021-2032)

9.3.5 South Korea Market Size and Forecast (2021-2032)

9.3.6 India Market Size and Forecast (2021-2032)

9.3.7 Southeast Asia Market Size and Forecast (2021-2032)

9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

10.1 South America Aluminum-doped Cobalt Tetroxide Sales Quantity by Type (2021-2032)

10.2 South America Aluminum-doped Cobalt Tetroxide Sales Quantity by Application (2021-2032)

10.3 South America Aluminum-doped Cobalt Tetroxide Market Size by Country

10.3.1 South America Aluminum-doped Cobalt Tetroxide Sales Quantity by Country

(2021-2032)

10.3.2 South America Aluminum-doped Cobalt Tetroxide Consumption Value by Country (2021-2032)

10.3.3 Brazil Market Size and Forecast (2021-2032)

10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Aluminum-doped Cobalt Tetroxide Sales Quantity by Type (2021-2032)

11.2 Middle East & Africa Aluminum-doped Cobalt Tetroxide Sales Quantity by Application (2021-2032)

11.3 Middle East & Africa Aluminum-doped Cobalt Tetroxide Market Size by Country

11.3.1 Middle East & Africa Aluminum-doped Cobalt Tetroxide Sales Quantity by Country (2021-2032)

11.3.2 Middle East & Africa Aluminum-doped Cobalt Tetroxide Consumption Value by Country (2021-2032)

11.3.3 Turkey Market Size and Forecast (2021-2032)

11.3.4 Egypt Market Size and Forecast (2021-2032)

11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)

11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

12.1 Aluminum-doped Cobalt Tetroxide Market Drivers

12.2 Aluminum-doped Cobalt Tetroxide Market Restraints

12.3 Aluminum-doped Cobalt Tetroxide Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Aluminum-doped Cobalt Tetroxide and Key Manufacturers

13.2 Manufacturing Costs Percentage of Aluminum-doped Cobalt Tetroxide

13.3 Aluminum-doped Cobalt Tetroxide Production Process

13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Aluminum-doped Cobalt Tetroxide Typical Distributors

14.3 Aluminum-doped Cobalt Tetroxide Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Receptor Agonist Properties, (USD Million), 2021 & 2025 & 2032

Table 3. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Medicinal Efficacy, (USD Million), 2021 & 2025 & 2032

Table 4. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Eli Lilly Basic Information, Manufacturing Base and Competitors

Table 6. Eli Lilly Major Business

Table 7. Eli Lilly GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 8. Eli Lilly GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. Eli Lilly Recent Developments/Updates

Table 10. Roche Basic Information, Manufacturing Base and Competitors

Table 11. Roche Major Business

Table 12. Roche GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 13. Roche GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. Roche Recent Developments/Updates

Table 15. Viking Therapeutics Basic Information, Manufacturing Base and Competitors

Table 16. Viking Therapeutics Major Business

Table 17. Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 18. Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Viking Therapeutics Recent Developments/Updates

Table 20. Asclepis Pharma Basic Information, Manufacturing Base and Competitors

Table 21. Asclepis Pharma Major Business

Table 22. Asclepis Pharma GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 23. Asclepis Pharma GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 24. Asclepis Pharma Recent Developments/Updates

Table 25. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and

Competitors

Table 26. Jiangsu Hengrui Medicine Major Business

Table 27. Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 28. Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 29. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 30. East China Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 31. East China Pharmaceutical Major Business

Table 32. East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 33. East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 34. East China Pharmaceutical Recent Developments/Updates

Table 35. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 36. Tonghua Dongbao Pharmaceutical Major Business

Table 37. Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 38. Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 39. Tonghua Dongbao Pharmaceutical Recent Developments/Updates

Table 40. Lepu Medical Technology Basic Information, Manufacturing Base and Competitors

Table 41. Lepu Medical Technology Major Business

Table 42. Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 43. Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 44. Lepu Medical Technology Recent Developments/Updates

Table 45. Hansoh Pharma Basic Information, Manufacturing Base and Competitors

Table 46. Hansoh Pharma Major Business

Table 47. Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 48. Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Sales Quantity (K Units),

Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 49. Hansoh Pharma Recent Developments/Updates

Table 50. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Manufacturer (2021-2026) & (K Units)

Table 51. Global GLP-1/GIPR Dual Peptide Agonist Revenue by Manufacturer (2021-2026) & (USD Million)

Table 52. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 53. Market Position of Manufacturers in GLP-1/GIPR Dual Peptide Agonist, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 54. Head Office and GLP-1/GIPR Dual Peptide Agonist Production Site of Key Manufacturer

Table 55. GLP-1/GIPR Dual Peptide Agonist Market: Company Product Type Footprint

Table 56. GLP-1/GIPR Dual Peptide Agonist Market: Company Product Application Footprint

Table 57. GLP-1/GIPR Dual Peptide Agonist New Market Entrants and Barriers to Market Entry

Table 58. GLP-1/GIPR Dual Peptide Agonist Mergers, Acquisition, Agreements, and Collaborations

Table 59. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 60. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Region (2021-2026) & (K Units)

Table 61. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Region (2027-2032) & (K Units)

Table 62. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Region (2021-2026) & (USD Million)

Table 63. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Region (2027-2032) & (USD Million)

Table 64. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Region (2021-2026) & (US\$/Unit)

Table 65. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Region (2027-2032) & (US\$/Unit)

Table 66. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 67. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 68. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Type

(2021-2026) & (USD Million)

Table 69. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Type

(2027-2032) & (USD Million)

Table 70. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Type (2021-2026) & (US\$/Unit)

Table 71. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Type (2027-2032) & (US\$/Unit)

Table 72. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 73. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 74. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Application (2021-2026) & (USD Million)

Table 75. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Application (2027-2032) & (USD Million)

Table 76. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Application (2021-2026) & (US\$/Unit)

Table 77. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Application (2027-2032) & (US\$/Unit)

Table 78. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 79. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 80. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 81. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 82. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 83. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2027-2032) & (K Units)

Table 84. North America GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 85. North America GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 86. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 87. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 88. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 89. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 90. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 91. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2027-2032) & (K Units)

Table 92. Europe GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 93. Europe GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 94. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 95. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 96. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 97. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 98. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Region (2021-2026) & (K Units)

Table 99. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Region (2027-2032) & (K Units)

Table 100. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Consumption Value by Region (2021-2026) & (USD Million)

Table 101. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Consumption Value by Region (2027-2032) & (USD Million)

Table 102. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 103. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 104. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 105. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 106. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 107. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country

(2027-2032) & (K Units)

Table 108. South America GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 109. South America GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 110. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 111. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 112. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 113. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 114. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 115. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2027-2032) & (K Units)

Table 116. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 117. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 118. GLP-1/GIPR Dual Peptide Agonist Raw Material

Table 119. Key Manufacturers of GLP-1/GIPR Dual Peptide Agonist Raw Materials

Table 120. GLP-1/GIPR Dual Peptide Agonist Typical Distributors

Table 121. GLP-1/GIPR Dual Peptide Agonist Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. GLP-1/GIPR Dual Peptide Agonist Picture

Figure 2. Global GLP-1/GIPR Dual Peptide Agonist Revenue by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Type in 2025

Figure 4. Injection Examples

Figure 5. Oral Administration Examples

Figure 6. Global GLP-1/GIPR Dual Peptide Agonist Revenue by Receptor Agonist Properties, (USD Million), 2021 & 2025 & 2032

Figure 7. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Receptor Agonist Properties in 2025

Figure 8. Balanced Examples

Figure 9. Biased Examples

Figure 10. Global GLP-1/GIPR Dual Peptide Agonist Revenue by Medicinal Efficacy, (USD Million), 2021 & 2025 & 2032

Figure 11. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Medicinal Efficacy in 2025

Figure 12. Long-acting Examples

Figure 13. Short-acting Examples

Figure 14. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 15. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Application in 2025

Figure 16. Diabetes Examples

Figure 17. Obesity Examples

Figure 18. Others Examples

Figure 19. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 20. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 21. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity (2021-2032) & (K Units)

Figure 22. Global GLP-1/GIPR Dual Peptide Agonist Price (2021-2032) & (US\$/Unit)

Figure 23. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Manufacturer in 2025

Figure 24. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Manufacturer in 2025

Figure 25. Producer Shipments of GLP-1/GIPR Dual Peptide Agonist by Manufacturer Sales (\$MM) and Market Share (%): 2025

Figure 26. Top 3 GLP-1/GIPR Dual Peptide Agonist Manufacturer (Revenue) Market Share in 2025

Figure 27. Top 6 GLP-1/GIPR Dual Peptide Agonist Manufacturer (Revenue) Market Share in 2025

Figure 28. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Region (2021-2032)

Figure 29. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value Market Share by Region (2021-2032)

Figure 30. North America GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 31. Europe GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 32. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 33. South America GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 34. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 35. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 36. Global GLP-1/GIPR Dual Peptide Agonist Consumption Value Market Share by Type (2021-2032)

Figure 37. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Type (2021-2032) & (US\$/Unit)

Figure 38. Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 39. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Application (2021-2032)

Figure 40. Global GLP-1/GIPR Dual Peptide Agonist Average Price by Application (2021-2032) & (US\$/Unit)

Figure 41. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 42. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 43. North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market

Share by Country (2021-2032)

Figure 44. North America GLP-1/GIPR Dual Peptide Agonist Consumption Value Market Share by Country (2021-2032)

Figure 45. United States GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 46. Canada GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 47. Mexico GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 48. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 49. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 50. Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Country (2021-2032)

Figure 51. Europe GLP-1/GIPR Dual Peptide Agonist Consumption Value Market Share by Country (2021-2032)

Figure 52. Germany GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 53. France GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 54. United Kingdom GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 55. Russia GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 56. Italy GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 57. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 58. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 59. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Region (2021-2032)

Figure 60. Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Consumption Value Market Share by Region (2021-2032)

Figure 61. China GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 62. Japan GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 63. South Korea GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 64. India GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 65. Southeast Asia GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 66. Australia GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 67. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 68. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 69. South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Country (2021-2032)

Figure 70. South America GLP-1/GIPR Dual Peptide Agonist Consumption Value Market Share by Country (2021-2032)

Figure 71. Brazil GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 72. Argentina GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 73. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 74. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 75. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity Market Share by Country (2021-2032)

Figure 76. Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Consumption Value Market Share by Country (2021-2032)

Figure 77. Turkey GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 78. Egypt GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 79. Saudi Arabia GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 80. South Africa GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032) & (USD Million)

Figure 81. GLP-1/GIPR Dual Peptide Agonist Market Drivers

Figure 82. GLP-1/GIPR Dual Peptide Agonist Market Restraints

Figure 83. GLP-1/GIPR Dual Peptide Agonist Market Trends

Figure 84. Porters Five Forces Analysis

Figure 85. Manufacturing Cost Structure Analysis of GLP-1/GIPR Dual Peptide Agonist in 2025

Figure 86. Manufacturing Process Analysis of GLP-1/GIPR Dual Peptide Agonist

Figure 87. GLP-1/GIPR Dual Peptide Agonist Industrial Chain

Figure 88. Sales Channel: Direct to End-User vs Distributors

Figure 89. Direct Channel Pros & Cons

Figure 90. Indirect Channel Pros & Cons

Figure 91. Methodology

Figure 92. Research Process and Data Source

I would like to order

Product name: Global GLP-1/GIPR Dual Peptide Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G10F1243AA91EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G10F1243AA91EN.html>